Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
biotech
boston blog main
boston top stories
life sciences
national blog main
national top stories
roche
4
×
boston
clinical trials
deals
san francisco blog main
san francisco top stories
avapritinib
blueprint medicines
cancer
cancer drugs
eli lilly
fda
genentech
investing
medullary thyroid cancer
non-small cell lung cancer
pralsetinib
selpercatinib
thyroid cancer
alexion pharmaceuticals
alnylam pharmaceuticals
amgen
boehringer ingelheim
capmatinib
cobimetinib
cstone pharmaceuticals
dicerna pharamceuticals
europe blog main
europe top stories
european medicines agency
fisogatinib
flatiron health
gastrointestinal stromal tumors
hepatitis b
What
drug
medicines
4
×
cancer
approval
blueprint
fda
research
ret
roche
team
address
approves
candidate
carries
caught
causing
certain
currently
designed
despite
dicerna
disease
eye
family
gene
genetic
hardest
hepatitis
hit
hottest
hunters
intended
ipo
latest
marketing
muscle
pact
pass
pay
pharma
Language
unset
Current search:
roche
×
photo
×
medicines
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug